Skip to Content

Posts tagged with "Uncategorized"

  • Chemical News

    Asking the Employees

    Every company that I’ve ever worked for has said that they want suggestions from the employees – some of them have been serious, and others were saying it because that’s the sort of thing you’re supposed to say. There are, naturally, all sorts of levels to consider. Some suggestions are small and easily implemented (or… Read More
  • Science Gifts 2014: Experiments at Home

    This is a repost of a “Science Gifts” suggestion from last year – from what I can see, the field hasn’t had any major additions in the past few months, and the recommendations below are all still relevant. Interesting science-gift ideas can be found in the “home experiments” area. There’s been a small boom… Read More
  • EMBL Chemical Biology: Polypharmacology

    Brian Shoichet is talking about the old days, 1930 to about 1985 or so. He mentions that Sir James Black called it “rational drug design” back then, which must have been a reaction to something that was considered really irrational. But these guys had a lot of advantages, which is what’s leading people back to… Read More
  • EMBL Chemical Biology: Substrate Activity Screening

    The day starts off with Jonathan Ellman talking about substrate activity screening, a very interesting technique that builds on optimized artificial enzyme substrates and turns them into inhibitors. He’s published a number of papers on this, and it looks like his current efforts are targeting phosphatases. I wish him luck with that; those hav… Read More
  • Bosutinib: Don’t Believe the Label!

    Now here’s a worrisome thought, if you’re doing kinase research. A tyrosine kinase inhibitor in the clinic against Bcr-Abl, bosutinib (SKI-606), is also being used as a research tool in a number of academic groups. But they’re probably not using what they think they’re using. This article has the details. The compound has a… Read More
  • The Academic-Industrial Collaboration in Drug Discovery Panel: Today

    As mentioned before, I’m going to be moderating a panel today on industry-academic collaborations in drug discovery at the SLAS meeting in San Diego. It starts at 10:30 AM Pacific Time, and you can access a live stream of the event here (scroll down). And if anyone has more questions on the subject they’d like… Read More
  • Day Off (In the U.K.)

    I’ll be wandering around London today – the med-chem part of my trip has finished up, and I’m taking a little time off before flying back to Boston later this weekend. I’ve already done some stereotypical London things (spending some quality time in the British Museum and having some very good Indian food), and will… Read More
  • Avandia Goes Out

    So Avandia (rosiglitazone) will be pulled from the market this fall. I’ve already written a few pieces on that whole market – PPAR ligands – but this still makes a person think. (See this post for the whole list). Starting in the mid-1990s or so, a huge amount of time, effort, and money went into… Read More
  • Benlysta for Lupus

    Congratulations to Human Genome Science (and their partners, GSK) for getting the first new lupus drug in 50 years through to approval. It has not been an easy road for Benlysta (belimumab), to put it lightly. Back in 2005, for example, the drug missed its endpoints in Phase II, and things didn’t look good. Further… Read More
  • The Escondido House of Explosives Goes Up – Live

    A reader has just sent me a link for a live video feed of the the (theoretically) controlled burn of the explosives-laden house that we were talking about here the other day. Word is that they’re scheduled to start at between 10 and 11 AM PST (2 to 3 PM on the East coast, 1800-1900… Read More